Can bird droppings cause lung infections in children with asthma on long-term Inhaled Corticosteroids (ICS) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bird Droppings and Lung Infections in Children on Long-Term ICS for Asthma

Children with asthma on long-term inhaled corticosteroids are theoretically at increased risk for opportunistic infections from bird droppings, but this risk is minimal at recommended low-to-medium ICS doses and does not warrant discontinuation of essential asthma therapy.

Understanding the Infection Risk

Bird droppings can transmit several pulmonary infections through inhalation of infectious agents:

  • Ornithosis (psittacosis), histoplasmosis, and cryptococcosis develop from inhalation of organisms present in infected bird droppings 1
  • These infections can cause severe pulmonary disease in exposed individuals 1
  • Pigeon-breeder's lung represents a hypersensitivity pneumonitis rather than infection, caused by allergic reaction to avian proteins 1

ICS Effects on Immune Function

The immunosuppressive concern with ICS in children is dose-dependent and clinically minimal at recommended doses:

  • Low-to-medium dose ICS (the preferred treatment for persistent asthma in children) have no clinically significant effects on hypothalamic-pituitary-adrenal (HPA) axis function in most children 2
  • Rare individuals may show increased susceptibility even at conventional doses, but this represents exceptional cases 2
  • Adrenal insufficiency is rare and confined to children receiving high doses of ICS 3, 4
  • Sensitive laboratory measures may show statistically significant changes in adrenal function, but these do not predict clinically meaningful immunosuppression 3

Risk-Benefit Analysis for Continuing ICS

The benefits of ICS therapy far outweigh theoretical infection risks:

  • ICS remain the preferred first-line therapy for persistent asthma in children of all ages, with strong evidence for improved outcomes including reduced exacerbations and hospitalizations 2, 5
  • For children 5 years and older with mild persistent asthma, low-dose ICS are the preferred therapy 2, 5
  • For children younger than 5 years, low-dose ICS via nebulizer, DPI, or MDI with holding chamber are recommended 2, 5
  • Uncontrolled asthma poses greater risks to morbidity and mortality than the minimal immunosuppression from appropriate-dose ICS 3, 4

Practical Management Approach

Continue ICS therapy at the lowest effective dose while implementing environmental precautions:

  • Do not discontinue or reduce ICS based solely on bird exposure concerns, as this would compromise asthma control 3, 6
  • Titrate ICS to the minimum effective dose required to maintain asthma control, which minimizes any systemic effects 7, 3
  • Implement strict avoidance of direct contact with birds, bird cages, and areas contaminated with bird droppings 1
  • Ensure proper inhaler technique to minimize swallowed drug and systemic absorption 3
  • Consider mouth rinsing after ICS administration to reduce local and systemic effects 8

When to Heighten Concern

Specific scenarios warrant increased vigilance:

  • Children receiving high-dose ICS (>medium dose range) have dose-related increased risk of systemic effects 2, 3, 4
  • Children on multiple forms of topical corticosteroids for concomitant allergic conditions face compounded risk 3
  • Direct, repeated exposure to bird droppings in enclosed spaces (e.g., cleaning bird cages, pigeon coops) represents higher-risk scenarios 1

Common Pitfalls to Avoid

  • Do not stop ICS therapy due to theoretical infection concerns without considering the proven mortality and morbidity risks of uncontrolled asthma 3, 6
  • Do not use high-dose ICS when low-to-medium doses provide adequate control 8, 3
  • Do not ignore environmental control measures—avoidance of bird exposure is the primary intervention for ornithopulmonary disease prevention 1

References

Research

Ornithopulmonary disease.

American family physician, 1979

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Safety of inhaled corticosteroids in children.

Pediatric pulmonology, 2002

Research

Systemic effects of inhaled corticosteroids in children.

Current opinion in pediatrics, 2004

Guideline

Asthma Management in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy of inhaled corticosteroids in asthma.

The Journal of allergy and clinical immunology, 1998

Guideline

Asthma Management in Children 5 Years and Younger

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.